|
|
Aw: Studien über Bimatoprost, latanoprost, prostaglandines induzieren Haarwuchs [Beitrag #214638 ist eine Antwort auf Beitrag #214636] :: Di., 08 November 2011 22:22
|
|
Studien über bimatoprost für die Wimpern
Eyelash Growth from Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes
Original Research Article Ophthalmology, Volume 117, Issue 5, May 2010, Pages 1024-1031 Sara Tullis Wester, Wendy W. Lee, Wei Shi
Participants
Nineteen subjects were enrolled.
Methods Subjects recruited from the Bascom Palmer Eye Institute were screened, and those who met inclusion criteria were enrolled. Each participant received 2 vials of gel suspension, which contained bimatoprost and normal saline, respectively, each mixed 1:1 with Gonak gel (Akorn Inc., Lake Forest, IL) and labeled "right eye" and "left eye" according to randomization. The suspension was applied to the upper eyelid eyelashes every evening on the designated eye for 6 weeks.
Main Outcome Measures
Lash length was measured with a caliper at enrollment, at weekly intervals during the application of the gel, and at 1 and 3 months after discontinuation of its use. Visual acuity, ocular symptoms, intraocular pressure, and photographs were documented at these same intervals.
Results
The mean eyelash growth from baseline in the bimatoprost group was 2.0 mm versus a mean of 1.1 mm in the placebo group, which was a statistically significant difference (P=0.009). The average intraocular pressure decreased equally in both groups (2 mmHg). No change in visual acuity or iris discoloration was noted in any of the subjects.
Conclusions
Our data showed an increase in eyelash length with the use of bimatoprost in gel suspension, suggesting the product's eyelash-lengthening properties.
-----------------------------------------------------------------------------------------------------------------------------------------------
Hypertrichosis of Vellus Hairs of the Malar Region After Unilateral Treatment With Bimatoprost
Jeffrey Hart, MD, and George Shafranov, MD
PURPOSE: To report hypertrichosis and increased pigmentation of vellus hairs of the malar region associated with
topical bimatoprost usage.
DESIGN: Interventional case report
METHODS: In a female Hispanic patient with open-angle glaucoma, hypertrichosis, and increased pigmentation of
the vellus hairs of the malar region developed after 8 weeks of unilateral treatment with bimatoprost. Increased
growth of eyelashes was also noted.
RESULTS: Bimatoprost was discontinued, with the intention of monitoring for resolution of hypertrichosis. The patient
epilated the hair because of poor cosmetic appearance. Two months after epilating the hair, growth did not recur.
CONCLUSIONS: Increased hair growth in the malar region can be an early side effect of topical use of ocular
bimatoprost.
-----------------------------------------------------------------------------------------------------------------------------------------------
Hypertrichosis of the eyelashes caused by bimatoprost
Antonella Tosti, MD,a Massimiliano Pazzaglia, MD,a Stylianos Voudouris, MD,a and Giovanni Tosti, MDb
Bologna and Trecenta-Rovigo, Italy
The phenyl-substituted analog of prostaglandin F2a, latanoprost (Xalatan; Pfizer, Inc, New York, NY) is an
intraocular pressure (IOP)-lowering drug for use in patients with glaucoma and ocular hypertension.
Latanoprost has been shown to stimulate eyelash hypertrichosis and has recently been proposed as
a possible treatment for alopecia areata involving the eyelashes. We report a case of hypertrichosis of the
eyelashes caused by the prostamide bimatoprost (Lumigan; Allergan, Inc, Irvine, Calif), a new IOPlowering
drug.
Eyelash growth in subjects treated with bimatoprost: A multicenter, randomized, double-masked, vehicle-controlled, parallel study
Stacy Smith, MD, Therapeutics Clinical Research, San Diego, CA, United States; Christine Somogyi, RN, Allergan, Inc., Irvine, CA, United States; Frederick Beddingfield, MD, PhD, Allergan, Inc., Irvine, CA, United States; Scott Whitcup, MD, Allergan, Inc., Irvine, CA, United States; Steven Fagien, MD, Private Practice, Boca Raton, FL, United States. Available online 24 February 2009.
Background: The safety and efficacy of bimatoprost 0.03% for the treatment of ocular hypertension has been well established in multiple randomized, double-masked, controlled clinical trials. In these studies, a significant proportion of patients demonstrated increased eyelash growth.
Methods: A prospective, randomized, double-masked, vehicle-controlled study was conducted to assess the efficacy and safety of bimatoprost 0.03% solution applied to the eyelid compared with vehicle in increasing eyelash prominence. A total of 278 healthy adult subjects were enrolled at 16 centers in North America. Eyelash prominence was assessed using a Global Eyelash Assessment (GEA) photonumeric scale. Secondary endpoints, including eyelash length, fullness, darkness, and patient reported outcomes, were also assessed.
Results: Statistically significantly increases in GEA responder rates were seen at the third study visit through the end of study including the primary endpoint (P < .0001).
Improvements from baseline in eyelash growth in length, fullness, and darkness were significantly greater in the bimatoprost group compared with the vehicle group at the primary endpoint and consistently at multiple other study visits before the primary endpoint. Subjects reported increased overall satisfaction with eyelash appearance and feelings of confidence, professionalism, and attractiveness, beginning at the third study visit (P ≤ .005). Adverse events reported more frequently in patients receiving bimatoprost included pruritus, conjunctival hyperemia, skin hyperpigmentation, and conjunctival hyperemia and were predominantly mild and occurred in <5% of subjects.
Conclusions: Topically applied bimatoprost 0.03% solution was found to be effective in increasing eyelash prominence and in increasing growth of natural eyelashes, and was safe and well tolerated in this study population of healthy adult subjects.
-----------------------------------------------------------------------------------------------------------------------------------------------
Hypertrichose malaire et ciliaire induite par le bimatoprost
A.-M. Rouxel , , A.-M. Roguedas-Contios, L. Misery
Service de Dermatologie, CHU Morvan, 2, avenue Foch, 29200 Brest
-----------------------------------------------------------------------------------------------------------------------------------------------
Eyelash growth in subjects treated with bimatoprost : A multicenter, randomized, double-masked, vehicle-controlled, parallel-group study
Previously presented at the Annual Meeting of the American Academy of Dermatology, San Francisco, CA, March 6-10, 2009.
Stacy Smith MDa, , , Steven Fagien MDb, Scott M. Whitcup MDc, Fred Ledon BSc, Christine Somogyi RNc, Emily Weng ScDc, Frederick C. Beddingfield III MD, PhDc, d
a Therapeutics Clinical Research, San Diego, California
b Private practice, Boca Raton, Florida
c Allergan, Inc, Irvine, California
d Division of Dermatology, David Geffen School of Medicine at University of CaliforniaLos Angeles, California
Accepted 6 June 2011. Available online 6 September 2011.
Bimatoprost 0.03% is associated with increased growth and prominence of eyelashes.
Objective We sought to compare the safety and efficacy of once-daily bimatoprost 0.03% versus vehicle in increasing eyelash length, thickness, and darkness after topical administration to upper eyelid margins.
Methods
In this 5-month study, subjects were randomized to receive once-daily bimatoprost 0.03% (n = 137) or vehicle (n = 141).
The primary end point was eyelash prominence assessed by the investigator global eyelash assessment scale. Secondary efficacy measures included eyelash length, thickness, and darkness measured by digital image analysis and patient-reported outcomes. Safety data included adverse event monitoring and ophthalmic examinations.
Results
A higher percentage of subjects treated with bimatoprost 0.03% (78.1%) versus vehicle (18.4%) demonstrated at least a 1-grade increase in global eyelash assessment score at week 16 (P < .0001). Subjects in the bimatoprost 0.03% group also had statistically significantly greater increases in eyelash length, thickness, and darkness (P < .0001) than those in the vehicle group. For adverse events, only conjunctival hyperemia occurred at a statistically significant higher incidence rate in the bimatoprost 0.03% versus the vehicle group (P = .03).
Limitations
Short-term duration of the trial was a limitation; black subjects were not enrolled secondary to technical requirements of digital image analysis.
Conclusion Bimatoprost 0.03% was found to be effective at enhancing eyelashes in adults with a very good safety profile.
|
Den Beitrag einem Moderator melden
|
|
|
|
|
|
|
|
Aw: Studien über Bimatoprost, latanoprost, prostaglandines induzieren Haarwuchs [Beitrag #225926 ist eine Antwort auf Beitrag #214635] :: Fr., 06 April 2012 16:55
|
|
ob das erste foto flaumhaare zeigt und das zweite terminalhaare sei mal dahingestellt
Bimatoprost ist ein Analogon von Prostaglandin F2α. Im Gegensatz zu den anderen Prostaglandin-Analoga liegt es nicht als Ester, sondern als Amid vor. Es wird deshalb auch als Prostamid-Analog bezeichnet.
Ein Analogon ist Strukturähnlichkeit. Sie bindet gleiche Rezeptoren wie eine andere Substanz.
[Aktualisiert am: Fr., 06 April 2012 17:27]
29 Jahre
Serenoa,
Grüner Tee,
Ell Cranell Alpha
Regaine Schaum
abgesetzt: Finasterid
warten auf: Haarmultiplikation
|
Den Beitrag einem Moderator melden
|
|
|
|
|
|
|
|
|
Aw: Studien über Bimatoprost, latanoprost, prostaglandines induzieren Haarwuchs [Beitrag #252936 ist eine Antwort auf Beitrag #252924] :: Mo., 07 Januar 2013 14:42
|
pilos
Beiträge: 26723 Registriert: November 2005 Ort: Ausland
Power Member ***** Top-User
|
kakaojoe schrieb am Mon, 07 January 2013 14:32Hier gibts Prostagladine f2 Alpha(glaube reines) sehr günstig zu kaufen .
Und E2.
Wenn das wirklich ist was ich denke, dann kaufe ich da sofort ein lol.
http://www.remedia.at/homoeopathie/Prostaglandin-E2/a5137.html
http://www.remedia.at/homoeopathie/Prostaglandin-F2-Alpha/a5263.html
Das sind aber kleinere Dosen. Je höher das C ist, deso niedriger ist die DOSIS. Der Ausgangsstoff wird 1in einem 1 : 100 Verdünnt. Dadurch entsteht die sog. Potenz C 1. Diese Potenz C1 wird nun nochmals 1:100 Verdünnt..
Mmh ja.. haha, Die Dosis wäre viiiiiel zu niedrig. 0,00000.....1.
Scheiss Homöopathie. Vll. kommt man bei denen an den Ausgangsstoff ran?
verbreitest du jetzt überall diesen SPAM..oder was
Die AGA-Behandlung ist individuell, eine Sache des "Trial And Error". Fasse dich kurz und kompakt bei Fragen... das ist meine Freizeit. Es besteht auch kein Verhältnis zu alopezie.de. ""Ich bin kein Arzt, sondern gebe hier lediglich meine private Meinung wieder; Art.5/GG. Auf Userfragen hin erläutere ich, wie ich persönlich vorgehen würde, wenn ich mich in der selben Lage befände. Bitte stets beachten: 1) Nachmachen auf eigene Gefahr und 2) Meine Vorschläge ersetzen keinen Arztbesuch!""
|
Den Beitrag einem Moderator melden
|
|
|
Aw: Studien über Bimatoprost, latanoprost, prostaglandines induzieren Haarwuchs [Beitrag #252983 ist eine Antwort auf Beitrag #252937] :: Mo., 07 Januar 2013 19:15
|
pilos
Beiträge: 26723 Registriert: November 2005 Ort: Ausland
Power Member ***** Top-User
|
kakaojoe schrieb am Mon, 07 January 2013 15:46
Ich arbeite für diese Firma und muss Frau nebst Kinder versorgen.
...dann lasst euch mal gescheitere produkte einfallen und keine esoterischen
Die AGA-Behandlung ist individuell, eine Sache des "Trial And Error". Fasse dich kurz und kompakt bei Fragen... das ist meine Freizeit. Es besteht auch kein Verhältnis zu alopezie.de. ""Ich bin kein Arzt, sondern gebe hier lediglich meine private Meinung wieder; Art.5/GG. Auf Userfragen hin erläutere ich, wie ich persönlich vorgehen würde, wenn ich mich in der selben Lage befände. Bitte stets beachten: 1) Nachmachen auf eigene Gefahr und 2) Meine Vorschläge ersetzen keinen Arztbesuch!""
|
Den Beitrag einem Moderator melden
|
|
|